Advertisement


Wyndham H. Wilson, MD, PhD, on Treating Diffuse Large B-Cell Lymphoma

2016 Pan Pacific Lymphoma Conference

Advertisement

Wyndham H. Wilson, MD, PhD, of the National Cancer Institute, discusses the molecular underpinnings of diffuse large B-cell lymphoma and targeted treatments.



Related Videos

Leukemia
Lymphoma

Susan M. O’Brien, MD, on ALL/Lymphoma: Upfront and Salvage Treatments in Older Patients

Susan M. O’Brien, MD, of the University of California, Irvine, discusses the challenges of treating older patients with acute lymphoblastic leukemia and lymphoma, and the positive res...

Lymphoma

Fredrick B. Hagemeister, Jr, MD, on Using Rituximab Maintenance

Fredrick B. Hagemeister, Jr, MD, of the University of Texas MD Anderson Cancer Center, discusses whether rituximab maintenance should be used in indolent lymphomas other than follicul...

Lymphoma

Andrew D. Zelenetz, MD, on Diffuse Large B-Cell Lymphoma: CHOP-R and EPOCH-R?

Andrew D. Zelenetz, MD, of Memorial Sloan Kettering Cancer Center, discusses the pros and cons of these two regimens, with or without another agent, in diffuse large B-cell lymphoma.

Lymphoma

Nathan Fowler, MD, and Sagar Lonial, MD, on Treating Follicular Lymphoma

Nathan H. Fowler, MD, of University of Texas MD Anderson Cancer Center, and Sagar Lonial, MD, of the Emory University School of Medicine, discuss managing early relap...

Lymphoma

Stephen M. Ansell, MD, PhD, on Precision Immunotherapy for Refractory Hodgkin Lymphoma

Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses the role of checkpoint inhibitors in Hodgkin lymphoma and the efficacy of nivolumab and pembrolizumab.

Advertisement

Advertisement



Advertisement